// App-Quantinova.ai

162 : Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476).

Researchers

Presenter

  • Nicholas D. James

Principal Investigators

  • Matthew Robert Sydes

  • Noel W. Clarke

  • Malcolm David Mason

  • David P. Dearnaley

  • Melissa Ruth Spears

  • Alastair W S Ritchie

  • J. Martin Russell

  • Chris C. Parker

  • Cyrill A. Rentsch

  • Jan Wallace

  • Jim Barber

  • Anna Lydon

  • Mahesh K B Parmar

Medical Centers

  • University of Warwick, Coventry, United Kingdom

  • MRC Clinical Trials Unit, UCL, London, United Kingdom

  • The Christie and Salford Royal Hospitals, Manchester, United Kingdom

  • Velindre NHS Trust, Cardiff, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • MRC Clinical Trials Unit, UCL, London, United Kingdom

  • MRC Clinical Trials Unit at UCL Aviation House, London, United Kingdom

  • Institute of Cancer Science, University of Glasgow, Glasgow, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • University Hospital Basel, Basel, Switzerland

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Velindre Cancer Centre, Cardiff

  • South Devon Healthcare NHS Foundation Trust, Torquay, United Kingdom

  • Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom

Locations

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Zoledronic acid

  • Celecoxib

  • ALT-210

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00268476

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved